Table 1.

Baseline characteristics of the study population

Characteristics	CD-A (n=93)	CD-R (n=69)	P value
Age	31±12	35±15	0.096
Sex (female)	36 (38.7%)	31 (44.9%)	0.427
Body mass index	19.5±3.9	20.8±4.3	0.049
Employment status	–	–	0.961
No	27 (29.0%)	21 (30.5%)
Retired	6 (6.5%)	3 (4.3%)
Yes	60 (64.5%)	45 (65.2%)
Living status	–	–	0.248
Alone	3 (3.2%)	6 (8.7%)
With others	90 (96.8%)	63 (91.3%)
Education	–	–	0.705
Up to 6 years	5 (5.4%)	4 (5.8%)
Up to 9 years	28 (30.1%)	18 (26.1%)
Up to 12 years	44 (47.3%)	34 (49.3%)
College	16 (17.2%)	13 (18.8%)
Marital status	–	–	0.579
Married/cohabitating	53 (57.0%)	34 (49.3%)
Widowed/divorced	7 (7.5%)	5 (7.2%)
Single	33 (35.5%)	30 (43.5%)
Montreal location	–	–	0.808
Ileal (L1)	35 (37.6%)	28 (40.7%)
Colonic (L2)	15 (16.2%)	5 (7.2%)
Ileocolon (L3)	39 (41.9%)	33 (47.8%)
Upper gastrointestinal tract (L4)	1 (1.1%)	0 (0%)
L4+L1/L2/L3	3 (3.2%)	3 (4.3%)
Montreal behaviour	–	–	0.401
Inflammatory	52 (55.9%)	45 (65.2%)
Structuring	24 (25.8%)	16 (23.2%)
Penetrating	17 (18.3%)	8 (11.6%)
Perianal disease	35 (37.6%)	28 (40.6%)	0.704
Current therapy	–	–	0.169
No treatment	0 (0%)	2 (2.9%)
Corticosteroids	8 (8.6%)	7 (10.1%)
5-aminosalicylates	21 (22.6%)	17 (24.6%)
Immunomodulators	27 (29.0%)	22 (31.9%)
Antitumour necrosis factor	16 (17.2%)	9 (13.0%)
Combined therapy	21 (22.6%)	12 (17.5%)
Anaemia	–	–	<0.001
No	36 (38.7%)	55 (79.7%)
Mild	49 (52.7%)	10 (14.5%)
Moderate	6 (6.5%)	3 (4.3%)
Severe	2 (2.1%)	1 (1.5%)
Relapses in the last year	–	–	<0.001
0	13 (14.0%)	35 (50.7%)
1–2	57 (61.3%)	24 (34.8%)
3	8 (8.6%)	8 (11.6%)
≥4	15 (16.1%)	2 (2.9%)
Disease duration (months)	13±25	11±19	0.594
C reactive protein	24.3±34.4	8.8±18.8	0.001

Note: Data are presented as the number (%) or mean±SD.

CD-A, Crohn’s disease patients in activity; CD-R, CD patients in remission.